The interaction between Epstein-Barr virus and multiple sclerosis genetic risk loci: insights into disease pathogenesis and therapeutic opportunities

被引:8
作者
Afrasiabi, Ali [1 ,2 ]
Ahlenstiel, Chantelle [3 ,4 ]
Swaminathan, Sanjay [1 ,5 ]
Parnell, Grant P. [1 ,6 ]
机构
[1] Univ Sydney, Westmead Inst Med Res, Ctr Immunol & Allergy Res, EBV Mol Lab, Sydney, NSW, Australia
[2] Univ New South Wales, Grad Sch Biomed Engn, Sydney, NSW, Australia
[3] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia
[4] Univ New South Wales, RNA Inst, Sydney, NSW, Australia
[5] Western Sydney Univ, Dept Med, Sydney, NSW, Australia
[6] Univ Sydney, Fac Med & Hlth, Sch Med Sci, Biomed Informat & Digital Hlth, Sydney, NSW, Australia
关键词
EBNA2; EBV; GWAS; multiple sclerosis; risk genetic variation; RNA therapeutics targeting EBV; T-LYMPHOCYTES; SEX-RATIO; IN-VIVO; ASSOCIATION; ANTIGENS; PATTERN; LATENCY; TWINS;
D O I
10.1002/cti2.1454
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multiple sclerosis (MS) is a chronic neurodegenerative autoimmune disease, characterised by the demyelination of neurons in the central nervous system. Whilst it is unclear what precisely leads to MS, it is believed that genetic predisposition combined with environmental factors plays a pivotal role. It is estimated that close to half the disease risk is determined by genetic factors. However, the risk of developing MS cannot be attributed to genetic factors alone, and environmental factors are likely to play a significant role by themselves or in concert with host genetics. Epstein-Barr virus (EBV) infection is the strongest known environmental risk factor for MS. There has been increasing evidence that leaves little doubt that EBV is necessary, but not sufficient, for developing MS. One plausible explanation is EBV may alter the host immune response in the presence of MS risk alleles and this contributes to the pathogenesis of MS. In this review, we discuss recent findings regarding how EBV infection may contribute to MS pathogenesis via interactions with genetic risk loci and discuss possible therapeutic interventions.
引用
收藏
页数:11
相关论文
共 106 条
  • [1] Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
    Adams, D.
    Gonzalez-Duarte, A.
    O'Riordan, W. D.
    Yang, C. -C.
    Ueda, M.
    Kristen, A. V.
    Tournev, I.
    Schmidt, H. H.
    Coelho, T.
    Berk, J. L.
    Lin, K. -P.
    Vita, G.
    Attarian, S.
    Plante-Bordeneuve, V.
    Mezei, M. M.
    Campistol, J. M.
    Buades, J.
    Brannagan, T. H., III
    Kim, B. J.
    Oh, J.
    Parman, Y.
    Sekijima, Y.
    Hawkins, P. N.
    Solomon, S. D.
    Polydefkis, M.
    Dyck, P. J.
    Gandhi, P. J.
    Goyal, S.
    Chen, J.
    Strahs, A. L.
    Nochur, S. V.
    Sweetser, M. T.
    Garg, P. P.
    Vaishnaw, A. K.
    Gollob, J. A.
    Suhr, O. B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) : 11 - 21
  • [2] Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial
    Adams, David
    Tournev, Ivailo L.
    Taylor, Mark S.
    Coelho, Teresa
    Plante-Bordeneuve, Violaine
    Berk, John L.
    Gonzalez-Duarte, Alejandra
    Gillmore, Julian D.
    Low, Soon-Chai
    Sekijima, Yoshiki
    Obici, Laura
    Chen, Chongshu
    Badri, Prajakta
    Arum, Seth M.
    Vest, John
    Polydefkis, Michael
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2023, 30 (01): : 18 - 26
  • [3] Genetic and transcriptomic analyses support a switch to lytic phase in Epstein Barr virus infection as an important driver in developing Systemic Lupus Erythematosus
    Afrasiabi, Ali
    Keane, Jeremy Thomas
    Ong, Lawrence T. C.
    Alinejad-Rokny, Hamid
    Fewings, Nicole Louise
    Booth, David Richmond
    Parnell, Grant Peter
    Swaminathan, Sanjay
    [J]. JOURNAL OF AUTOIMMUNITY, 2022, 127
  • [4] Quantitative neurogenetics: applications in understanding disease
    Afrasiabi, Ali
    Keane, Jeremy T.
    Heng, Julian Ik-Tsen
    Palmer, Elizabeth E.
    Lovell, Nigel H.
    Alinejad-Rokny, Hamid
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2021, 49 (04) : 1621 - 1631
  • [5] The Interaction of Human and Epstein-Barr Virus miRNAs with Multiple Sclerosis Risk Loci
    Afrasiabi, Ali
    Fewings, Nicole L.
    Schibeci, Stephen D.
    Keane, Jeremy T.
    Booth, David R.
    Parnell, Grant P.
    Swaminathan, Sanjay
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (06) : 1 - 15
  • [6] The interaction of Multiple Sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis
    Afrasiabi, Ali
    Parnell, Grant P.
    Swaminathan, Sanjay
    Stewart, Graeme J.
    Booth, David R.
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [7] Evidence from genome wide association studies implicates reduced control of Epstein-Barr virus infection in multiple sclerosis susceptibility
    Afrasiabi, Ali
    Parnell, Grant P.
    Fewings, Nicole
    Schibeci, Stephen D.
    Basuki, Monica A.
    Chandramohan, Ramya
    Zhou, Yuan
    Taylor, Bruce
    Brown, David A.
    Swaminathan, Sanjay
    McKay, Fiona C.
    Stewart, Graeme J.
    Booth, David R.
    [J]. GENOME MEDICINE, 2019, 11 (1)
  • [8] Functional Epstein-Barr virus reservoir in plasma cells derived from infected peripheral blood memory B cells
    Al Tabaa, Yassine
    Tuaillon, Edouard
    Bollore, Karine
    Foulongne, Vincent
    Petitjean, Gael
    Seigneurin, Jean-Marie
    Duperray, Christophe
    Desgranges, Claude
    Vendrell, Jean-Pierre
    [J]. BLOOD, 2009, 113 (03) : 604 - 611
  • [9] MicroRNAs of Epstein-Barr Virus Control Innate and Adaptive Antiviral Immunity
    Albanese, Manuel
    Tagawa, Takanobu
    Buschle, Alexander
    Hammerschmidt, Wolfgang
    [J]. JOURNAL OF VIROLOGY, 2017, 91 (16)
  • [10] Arvin A, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P700